A.Univ.Prof. Paul Knoebl, MD
Department of Medicine I (Division of Hematology and Hemostaseology)
Position: Associate Professor
ORCID: 0000-0002-7909-7225
T +43 1 40400 49560
paul.knoebl@muv.ac.at
Keywords
Anticoagulants; Critical Illness; Hemophilia A; Protein C; Purpura Fulminans; Rare Diseases; Sepsis; Thrombotic Microangiopathies; von Willebrand Factor
Research interests
- Immune mediated coagulation disorders (incl. acquired hemophilia, antiphospholipid antibodies, immune thrombocytopenia)
- Thrombotic microangiopathy (incl. thrombotic thrombocytopenic purpura, Upshaw.Schulman Syndrome, hemolytic uremic syndrome, etc.)
- Critical illness coagulopathy (incl. purpura fulminans, sepsis, etc.)
- rare bleeding disorders
Techniques, methods & infrastructure
- ROTEM
- Anti-ADAMTS13 antibody ELISA
Selected publications
- Scully, M. et al., 2019. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine. Available at: http://dx.doi.org/10.1056/NEJMoa1806311.
- Peyvandi, F. et al., 2016. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 374(6), pp.511-522. Available at: http://dx.doi.org/10.1056/NEJMoa1505533.
- KNOEBL, P. et al., 2012. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis, 10(4), pp.622-631. Available at: http://dx.doi.org/10.1111/j.1538-7836.2012.04654.x.
- Knöbl, P., 2018. Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A. Drugs, 78(18), pp.1861-1872. Available at: http://dx.doi.org/10.1007/s40265-018-1027-y.
- Knöbl, P., 2017. New treatment options for thrombotic thrombocytopenic purpura. Hämostaseologie, 37(03), pp.211-215. Available at: http://dx.doi.org/10.5482/HAMO-16-07-0026.